202 related articles for article (PubMed ID: 24445868)
1. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
[No Abstract] [Full Text] [Related]
2. Changes in allele frequencies of
Nooruddin Z; Miltgen N; Wei Q; Schowinsky J; Pan Z; Tobin J; Purev E; Gutman JA; Robinson W; Pollyea DA
Haematologica; 2017 May; 102(5):e207-e209. PubMed ID: 28209656
[No Abstract] [Full Text] [Related]
3. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
4. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
6. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
Ann Hematol; 2015 May; 94(5):879-80. PubMed ID: 25491280
[No Abstract] [Full Text] [Related]
7. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
[No Abstract] [Full Text] [Related]
8. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
9. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
10. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
11. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
Hinze A; Rinke J; Hochhaus A; Ernst T
Ann Hematol; 2021 Feb; 100(2):581-584. PubMed ID: 32577845
[No Abstract] [Full Text] [Related]
12. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
14. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
[TBL] [Abstract][Full Text] [Related]
15. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
16. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
18. [CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].
Cui Y; Li B; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1069-73. PubMed ID: 25543699
[TBL] [Abstract][Full Text] [Related]
19. CSF3R-, ASXL1-, and SETBP1-mutated chronic neutrophilic leukemia with monoclonal gammopathy of undetermined significance in a patient who developed severe ascites due to sinusoidal neutrophilic infiltration.
Harada N; Mukai D; Izuta Y; Shibano I; Kizawa Y; Shiragami H; Ohnishi N; Hosaka N; Mugitani A
Pathol Int; 2024 Feb; 74(2):93-95. PubMed ID: 38050833
[No Abstract] [Full Text] [Related]
20. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]